Key Points
- Director George Morrow sold 7,500 shares for about $1.09 million at an average price of $145.79. The sale was made under a pre-arranged Rule 10b5-1 plan; he retained 10,386 shares.
- Neurocrine reported quarterly EPS of $3.29, beating the $1.91 consensus, and revenue of $1.12 billion, up 41% year over year and above estimates. The company also raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion.
- Analysts’ consensus rating was “Moderate Buy”, with an average price target of $201.55; several firms raised targets following the quarterly results.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director George Morrow sold 300 shares of the stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $149.00, for a total value of $44,700.00. Following the transaction, the director owned 10,386 shares in the company, valued at $1,547,514. This represents a 2.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Neurocrine Biosciences Price Performance
Shares of NASDAQ:NBIX opened at $164.85 on Wednesday. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $186.12. The firm has a market capitalization of $16.76 billion, a price-to-earnings ratio of 24.46, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. The business's 50 day moving average price is $146.72 and its 200-day moving average price is $147.60.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The firm's revenue was up 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.04 EPS. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current year.
Key Stories Impacting Neurocrine Biosciences
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, exceeding estimates, while EPS of $3.29 also topped consensus. Product sales surpassed $1 billion for the first time. Neurocrine raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, citing demand across its portfolio. Third-quarter results
- Positive Sentiment: Several analysts raised price targets after the results: Canaccord to $220, Piper Sandler to $215, RBC to $190, and Morgan Stanley to $185. Ratings ranged from buy/outperform to equal weight, so the target increases were broadly supportive but not uniformly bullish.
- Positive Sentiment: The company said it has begun a Phase 2 Alzheimer’s study and plans to present its neuroscience work and pipeline at the NEI Fall Congress. These updates add to investor focus on longer-term development opportunities, though the supplied reports provide limited study details. Alzheimer’s study and education update
- Negative Sentiment: Director George J. Morrow reported sales totaling 15,000 shares across transactions on November 2–3, in addition to a 300-share sale on October 30. The filings say the transactions were made under a pre-arranged Rule 10b5-1 plan, which may temper concern, and he retained 10,386 shares.
Hedge Funds Weigh In On Neurocrine Biosciences
Institutional investors have recently added to or reduced their stakes in the stock. Candriam S.C.A. increased its stake in shares of Neurocrine Biosciences by 32.2% in the 3rd quarter. Candriam S.C.A. now owns 344,883 shares of the company's stock worth $49,097,000 after acquiring an additional 83,957 shares during the last quarter. Ethic Inc. boosted its position in shares of Neurocrine Biosciences by 11.1% during the 3rd quarter. Ethic Inc. now owns 1,909 shares of the company's stock valued at $271,000 after acquiring an additional 191 shares during the last quarter. Formidable Asset Management LLC acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at about $428,000. AlphaCentric Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 5.2% in the third quarter. AlphaCentric Advisors LLC now owns 10,230 shares of the company's stock valued at $1,451,000 after purchasing an additional 503 shares during the period. Finally, Parallel Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 3.5% in the third quarter. Parallel Advisors LLC now owns 1,780 shares of the company's stock valued at $252,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.
Wall Street Analysts Forecast Growth
NBIX has been the subject of a number of research reports. Needham & Company LLC reissued a "buy" rating and set a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday, October 16th. Citigroup raised their price target on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the company a "buy" rating in a research note on Thursday, September 3rd. Guggenheim started coverage on Neurocrine Biosciences in a report on Tuesday, October 6th. They issued a "buy" rating and a $207.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $210.00 to $220.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Royal Bank Of Canada increased their target price on Neurocrine Biosciences from $187.00 to $190.00 and gave the company an "outperform" rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $201.55.
Check Out Our Latest Stock Report on Neurocrine Biosciences
About Neurocrine Biosciences
(
Get Free Report)
Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.
Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
